SeaStar Medical Holding Corporation (ICU)
- Previous Close
1.2500 - Open
1.2500 - Bid 1.2400 x 100
- Ask 1.3000 x 100
- Day's Range
1.2400 - 1.3000 - 52 Week Range
1.1100 - 13.8470 - Volume
145,384 - Avg. Volume
175,325 - Market Cap (intraday)
12.45M - Beta (5Y Monthly) -0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-6.6300 - Earnings Date May 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
seastarmedical.comRecent News: ICU
View More
Performance Overview: ICU
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICU
View MoreValuation Measures
Market Cap
12.45M
Enterprise Value
11.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
35.22
Price/Book (mrq)
--
Enterprise Value/Revenue
83.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-272.95%
Return on Equity (ttm)
--
Revenue (ttm)
135k
Net Income Avi to Common (ttm)
-24.83M
Diluted EPS (ttm)
-6.6300
Balance Sheet and Cash Flow
Total Cash (mrq)
1.82M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.16M